Azacitidine-induced Hepatotoxicity in a Patient with Myelodysplastic Syndrome.
10.5045/kjh.2007.42.2.176
- Author:
Jin Soo KIM
1
;
Joo Han LIM
;
Hyeon Gyu YI
;
Hyunmin PARK
;
Moon Hee LEE
;
Chul Soo KIM
Author Information
1. Division of Hematology/Oncology, Departments of Medicine, Inha University Hospital, Incheon,
- Publication Type:Case Report
- Keywords:
Myelodysplastic syndrome;
Azacitidine;
Adverse effects;
Hepatitis;
Toxic;
Hepatitis;
Drug-induced
- MeSH:
Aged;
Azacitidine;
Cholelithiasis;
Classification;
Hematopoietic Stem Cell Transplantation;
Hepatitis;
Humans;
Liver;
Liver Cirrhosis;
Myelodysplastic Syndromes*;
Prevalence;
United States Food and Drug Administration
- From:Korean Journal of Hematology
2007;42(2):176-179
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hematopoietic stem cell transplantation remains the only curative option for myelodysplastic syndrome (MDS), but the prevalence of the disease in elderly people limits broad application of the procedure, particularly in lower risk group. Azacitidine has been recently approved by the U.S. Food and Drug Administration for MDS regardless of subtype on French-American-British classification. Adverse effects of azacitidine include gastrointestinal, hematological and infusion-related reactions. Azacitidine induced hepatotoxicity has been reported mainly in patients with previous hepatobiliary disease, e.g., extensive tumor infiltration in liver, liver cirrhosis and cholelithiasis. We report here a case of azacitidine-induced hepatitis under no predisposition to hepatobiliary disease.
